ANDA 216502, held by Amneal Pharmaceuticals. Methylprednisolone Acetate.
As of Nov 21, 2026, ANDA 216502 (Methylprednisolone Acetate), held by Amneal Pharmaceuticals, was first approved by FDA on Nov 3, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 3, 2023 | Original application | Approved | None posted |
| Methylprednisolone Acetate40MG/ML · injectable;injection | Methylprednisolone Acetate | Rx |
| Methylprednisolone Acetate80MG/ML · injectable;injection | Methylprednisolone Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters